2015
DOI: 10.1007/s00586-015-4239-9
|View full text |Cite
|
Sign up to set email alerts
|

The effect of serotonin–noradrenaline reuptake inhibitor duloxetine on the intervertebral disk-related radiculopathy in rats

Abstract: SNRI duloxetine inhibited neuropathic pain in rats possibly via down-regulating TNF, NGF, and microglia activation. We conclude that duloxetine, and most likely other SNRIs, may be used for the management of lumbar neuropathic pain.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
9
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 22 publications
(10 citation statements)
references
References 55 publications
1
9
0
Order By: Relevance
“…The authors emphatically indicated that duloxetine might be effective in patients with persistent, NSAID‐resistant neuropathic OA pain, and it might diminish the number of patients requiring joint replacement surgery in the future . In addition, duloxetine improved the sensitivity to non‐noxious mechanical stimuli measured by a pain behavioral test in the intervertebral disc‐related radiculopathy model in rats, which is truly regarded as a model for neuropathic pain . With regard to clinical results, several studies conducted in the United States, Europe, and Asia have shown significant improvements in pain, joint junction and function, and health‐related quality of life for patients with hip or knee OA who were treated with duloxetine compared with placebo without serious adverse events .…”
Section: Discussionsupporting
confidence: 52%
See 2 more Smart Citations
“…The authors emphatically indicated that duloxetine might be effective in patients with persistent, NSAID‐resistant neuropathic OA pain, and it might diminish the number of patients requiring joint replacement surgery in the future . In addition, duloxetine improved the sensitivity to non‐noxious mechanical stimuli measured by a pain behavioral test in the intervertebral disc‐related radiculopathy model in rats, which is truly regarded as a model for neuropathic pain . With regard to clinical results, several studies conducted in the United States, Europe, and Asia have shown significant improvements in pain, joint junction and function, and health‐related quality of life for patients with hip or knee OA who were treated with duloxetine compared with placebo without serious adverse events .…”
Section: Discussionsupporting
confidence: 52%
“…In a mouse model of diabetic neuropathy, the peripheral and central neuroprotective effects of duloxetine in neuropathic pain were, at least in part, related to its downregulation in the spinal astrocytes and microglia . In another study, the occurrence of activated microglia labeled with Iba1 was tested in a disc‐related radiculopathy model in rats and duloxetine‐inhibited microglia activation . Duloxetine is classified as an SNRI that influences the descending pain modulatory system; therefore, it is assumed that duloxetine dampens pain via the descending pain modulatory system, and this may affect the expression of either Iba1 or microglial chemotaxis from different areas.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In contrast, some studies showed that the level of spinal serotonin increased or was not changed after spinal nerve injury [ 25 , 26 ]. Two recent experimental studies have shown that using selective serotonin or serotonin–noradrenaline reuptake inhibitors may be associated with reduction of neuropathic pain related to lumbar disk herniation and inhibition of tumor necrosis factor expression after two or three weeks of treatment suggesting the pronociceptive feature of serotonin in lumbar disk herniation-related pain [ 27 , 28 ]. On the other hand, in a systematic review by Urquhart et al, in 2008, including nine randomized controlled trials, no significant relief in chronic low back pain was observed in patients who were treated with SSRIs [ 29 ].…”
Section: Discussionmentioning
confidence: 99%
“…Inhibition of microglial activation has been recently identified as a new mechanism which strongly contributes to the analgesic effects of duloxetine (Kremer et al, 2018; Tawfik et al, 2018). The first evidence in this regard comes from studies carried out in animal models of chemotherapy-induced neuropathy (Greish et al, 2014) and intervertebral disc-related neuropathic pain (Handa et al, 2016). Furthermore, the inhibition of mechanical allodynia and thermal hyperalgesia induced by duloxetine, in a mouse model of diabetic neuropathy, was paralleled by a significant reduction of specific markers of microglia (CD11b) and astrocyte (GFAP) activation (Tawfik et al, 2018).…”
Section: Rescue Of Noradrenergic System As a Novel Pharmacological Apmentioning
confidence: 99%